Prognostic Predictors: Genetic Signatures, Adjuvant!, and PREDICT
Predictive factors are responsible in determining the recurrence risk and death related to cancer and therefore to stablish the natural history of the disease regardless the treatment performed. Predictive factors are those that determine the outcome to a treatment.
KeywordsGenomic profile Oncotype DX Mammaprint Prognostic Prediction
- 1.Allison KH, Kandalaft PL, Sitlani CM, Dintzis SM, Gown AM. Routine pathologic parameters can predict Oncotype DX recurrence scores in subsets of ER positive patients: who does not always need testing? Breast Cancer Res Treat. 2012;131(2):413–24. Algorithm based on pathological anatomy that suggests which patients do not need to undergo OncotypeDx analysis in the decision-making process.CrossRefGoogle Scholar
- 4.Harris LN, Ismaila N, McShane LM, et al. Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2016;34:1134–50. ASCO’s guideline on the recommendations of molecular signatures. This publication was updated in 2017 after the publication of the MINDACT study.CrossRefGoogle Scholar
- 5.Krop I, Ismaila N, Andre F, Bast RC, et al. Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update. J Clin Oncol. 2017. Atualização da diretriz da ASCO publicada em 2016, com foco nos resultados do estudo randomizado MINDACT, ampliando a recomendação do teste Mammaprint. ASCO’s updated guideline published in 2016, emphasizing the results of the randomized MINDACT study, extending the recommendation of the Mammaprint test.Google Scholar
- 7.Wishart GC, Bajdik CD, Dicks E, et al. PREDICT Plus: development and validation of a prognostic model for early breast cancer that includes HER2. Br J Cancer. 2012;107(5):800–7. This study demonstrates the value of the PREDICT tool versus Adjuvant! and demonstrates that the PREDICT, incorporating the status of HER2, is more accurate.CrossRefGoogle Scholar